Sepsis for APRNs Nursing CE Course
Tracking # 20-885912
Course overview
This module aims to provide an overview of sepsis, its risk factors, clinical features, best practices for diagnosis, and treatment to inform practice and help APRNs provide optimal care, patient education, and support improved patient outcomes and decreased mortality.
Subject areas
This course counts toward the state boards and subject areas below.
Arkansas State Board of Nursing
Certified Nurse Midwife
1h
Pharmacotherapeutics continuing education in the area of certification
2.5h
Practice-Focused Continuing Education
Certified Nurse Practitioner
1h
Pharmacotherapeutics continuing education in the area of certification
2.5h
Practice-Focused Continuing Education
Clinical Nurse Specialist
2.5h
Practice-Focused Continuing Education
1h
Pharmacotherapeutics continuing education in the area of certification
Registered Nurse Practitioner
3.5h
Practice-Focused Continuing Education
District of Columbia Board of Nursing
Certified Nurse Midwife
2.5h
Relevant to Clinical Nurse Midwife Specialty
1h
Pharmacology Component
Clinical Nurse Specialist
2.5h
Relevant to Clinical Nurse Specialty
1h
Pharmacology Component
Nurse Practitioner
1h
Pharmacology Component
2.5h
Relevant to Nurse Practitioner Specialty
Florida Board of Nursing
Advanced Practice Registered Nurse
2.5h
General
1h
Pharmacology for Autonomous Practice Initial Certification
New Mexico Board of Nursing
Certified Nurse Practitioner
1h
Continuing education related to pharmacology
2.5h
Continuing education relevant to nursing practice
Certified Registered Nurse Anesthetist
2.5h
Continuing education relevant to nursing practice
1h
Continuing education related to pharmacology
Clinical Nurse Specialist
1h
Continuing education related to pharmacology
2.5h
Continuing education relevant to nursing practice
South Carolina Board of Nursing
Advanced Practice Registered Nurse
1h
Pharmacotherapeutics
2.5h
General
West Virginia Board of Registered Nurses
Advanced Practice Registered Nurse
2.5h
Clinical Management of Patients
1h
Prescriptive Authority Privilege (RXA) pharmacotherapeutic